Supriya Lifescience Limited (NSE:SUPRIYA)

India · Delayed Price · Currency is INR

644.45

+6.55 (1.03%)

Nov 12, 2026, 3:29 PM IST

Market Cap	51.87B -14.8%
Revenue (ttm)	8.79B +22.9%
Net Income	1.77B -2.8%
EPS	22.01 -3.0%
Shares Out	80.48M
PE Ratio	29.28
Forward PE	n/a
Dividend	1.00 (0.16%)
Ex-Dividend Date	Sep 4, 2026

Volume	412,039
Open	642.70
Previous Close	637.90
Day's Range	633.80 - 644.55
52-Week Range	545.50 - 1,085.00
Beta	0.67
Analysts	Hold
Price Target	765.00 (+18.71%)
Earnings Date	Nov 6, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1987

Employees 607

Stock Exchange National Stock Exchange of India

Ticker Symbol SUPRIYA

Full Company Profile

Financial Performance

In fiscal year 2026, Supriya Lifescience's revenue was 8.28 billion, an increase of 18.86% compared to the previous year's 6.96 billion. Earnings were 2.09 billion, an increase of 11.26%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for SUPRIYA stock is "Hold." The 12-month stock price target is ₹765.00, which is an increase of 18.71% from the latest price.

Price Target

₹765.00

(18.71% upside)

Analyst Consensus: Hold

Stock Forecasts